drugset / Trial / NCT06422377

A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

NCT06422377

Phase 3 Terminated 1 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to check how soticlestat impacts symptoms of Dravet syndrome \[DS\] and Lennox-Gastaut syndrome \[LGS\] in participants who have been exposed to fenfluramine.

Timeline

Start
2024-04-25
Primary completion
2024-08-14
Completion
2024-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Soticlestat Small molecule 200 mg Oral